AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, today announced that it has signed a contract to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. Systems will be placed at sites throughout Europe and North America. The value of the contract is approximately US$3.2 million.
Duncan Ross, CEO of AtCor Medical said, "We are delighted to have secured this significant contract. This, together with the pharmaceutical contract announced in August, represents a very good start to our financial year.
"This contract is with an existing client that we have worked with for a number of years. The non- invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs. It is encouraging that AtCor's gold standard technology, data management and support services are being validated through repeat business from the pharmaceutical sector." About AtCor Medical
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,900 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 600 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe.